Integrated BioTherapeutics, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Integrated BioTherapeutics, Inc. – Product Pipeline Review – 2016’, provides an overview of the Integrated BioTherapeutics, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Integrated BioTherapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Integrated BioTherapeutics, Inc.

The report provides overview of Integrated BioTherapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Integrated BioTherapeutics, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Integrated BioTherapeutics, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Integrated BioTherapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Integrated BioTherapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Integrated BioTherapeutics, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Integrated BioTherapeutics, Inc. Snapshot 5

Integrated BioTherapeutics, Inc. Overview 5

Key Information 5

Key Facts 5

Integrated BioTherapeutics, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Integrated BioTherapeutics, Inc. - Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products - Monotherapy 9

Pipeline Products - Combination Treatment Modalities 10

Integrated BioTherapeutics, Inc. - Pipeline Products Glance 11

Integrated BioTherapeutics, Inc. - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Integrated BioTherapeutics, Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Integrated BioTherapeutics, Inc. - Drug Profiles 14

STEBVax 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

(Ebola + Marburg) vaccine 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Antibodies for Ebola and Marburg Viral Infections 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

AT-62aa 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Monoclonal Antibodies for Ebola and Marburg Infections 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibodies for Equine Encephalitis and Chikungunya 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody 1 for Staphylococcus Aureus Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Integrated BioTherapeutics, Inc. - Pipeline Analysis 26

Integrated BioTherapeutics, Inc. - Pipeline Products by Target 26

Integrated BioTherapeutics, Inc. - Pipeline Products by Route of Administration 27

Integrated BioTherapeutics, Inc. - Pipeline Products by Molecule Type 28

Integrated BioTherapeutics, Inc. - Pipeline Products by Mechanism of Action 29

Integrated BioTherapeutics, Inc. - Recent Pipeline Updates 30

Integrated BioTherapeutics, Inc. - Dormant Projects 31

Integrated BioTherapeutics, Inc. - Locations And Subsidiaries 32

Head Office 32

Appendix 33

Methodology 33

Coverage 33

Secondary Research 33

Primary Research 33

Expert Panel Validation 33

Contact Us 33

Disclaimer 34

List of Tables

List of Tables

Integrated BioTherapeutics, Inc., Key Information 5

Integrated BioTherapeutics, Inc., Key Facts 5

Integrated BioTherapeutics, Inc. – Pipeline by Indication, 2016 7

Integrated BioTherapeutics, Inc. – Pipeline by Stage of Development, 2016 8

Integrated BioTherapeutics, Inc. – Monotherapy Products in Pipeline, 2016 9

Integrated BioTherapeutics, Inc. – Combination Treatment Modalities in Pipeline, 2016 10

Integrated BioTherapeutics, Inc. – Phase I, 2016 11

Integrated BioTherapeutics, Inc. – Preclinical, 2016 12

Integrated BioTherapeutics, Inc. – Discovery, 2016 13

Integrated BioTherapeutics, Inc. – Pipeline by Target, 2016 26

Integrated BioTherapeutics, Inc. – Pipeline by Route of Administration, 2016 27

Integrated BioTherapeutics, Inc. – Pipeline by Molecule Type, 2016 28

Integrated BioTherapeutics, Inc. – Pipeline Products by Mechanism of Action, 2016 29

Integrated BioTherapeutics, Inc. – Recent Pipeline Updates, 2016 30

Integrated BioTherapeutics, Inc. – Dormant Developmental Projects,2016 31

List of Figures

List of Figures

Integrated BioTherapeutics, Inc. – Pipeline by Indication, 2016 7

Integrated BioTherapeutics, Inc. – Pipeline by Stage of Development, 2016 8

Integrated BioTherapeutics, Inc. – Monotherapy Products in Pipeline, 2016 9

Integrated BioTherapeutics, Inc. – Pipeline by Target, 2016 26

Integrated BioTherapeutics, Inc. – Pipeline by Molecule Type, 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports